BioNTech Puts $1 Billion on the Table as Pumitamig Faces Its Pivotal ASCO Moment
21.05.2026 - 14:01:32 | boerse-global.de
BioNTech is entering a make-or-break week. With the annual ASCO cancer conference now releasing more than 7,000 study abstracts, the Mainz-based biotech is betting its pipeline future on a single experimental drug. Pumitamig, a bispecific antibody targeting solid tumors, faces its first major readout from the Phase 2 ROSETTA Lung-02 trial in first-line non-small cell lung cancer, where it is taking on the established standard, Merck’s Keytruda (pembrolizumab). The results will test whether BioNTech can truly pivot from a pandemic vaccine maker into a commercial oncology powerhouse.
That strategic shift is being reinforced at the governance level. At the annual general meeting on May 15, 2026, shareholders approved expanding the supervisory board from six to eight members. Two new faces — Prof. Iris Löw-Friedrich and Dr. Susanne Schaffert — bring deep oncology and pharmaceutical commercialization experience. The appointments signal that the company’s focus is no longer on COVID-related revenues but on building a lasting cancer franchise.
Deepening Losses, Hefty Cash Cushion
The transition is expensive. BioNTech posted first-quarter 2026 revenue of just €118.1 million, while its net loss widened to €531.9 million as R&D spending surged. The burn rate underscores the pressure to deliver clinical milestones. Yet the balance sheet offers considerable breathing room: nearly $20 billion in cash reserves provide a runway that few biotechs can match.
Management is deploying part of that capital to prop up the stock. In May, the company authorized a $1 billion buyback program for its American Depositary Shares. The move aims to return capital to shareholders during a particularly weak patch for the equity and to signal confidence in the underlying valuation.
Should investors sell immediately? Or is it worth buying BioNTech?
Stock Under Pressure Despite Institutional Buying
The shares have taken a beating. BioNTech’s stock recently traded at around €77.95–€77.65, down roughly 17% over the past month and sitting about 10% below the 200-day moving average. That technical weakness has not scared off all institutional investors. Leonteq Securities AG purchased 27,427 ADS worth approximately $2.61 million. Larson Financial boosted its stake by 86.4%, while ProShare Advisors added 24.6%.
Analysts remain broadly constructive. The consensus rating is “Moderate Buy,” with price targets ranging from $124.26 to $130.60. Cash-flow-based models suggest the market is only cautiously pricing in future pipeline success. Long-term projections envision a return to profitability by 2029, with estimated revenues of €2.5 billion and net income of €374.1 million. Optimistic scenarios stretch to €3.1 billion in sales and €587.7 million in profit.
Pipeline Beyond Pumitamig
While all eyes are on the Pumitamig data, other programs are advancing. Two new studies for Pumitamig have been unveiled, including one targeting stage III lung cancer. Five additional registrational trials began this year in collaboration with Bristol Myers Squibb. Meanwhile, BioNTech expects interim results from a Phase 3 trial of its antibody Gotistobart later in 2026, with primary data collection ending as early as June.
BioNTech at a turning point? This analysis reveals what investors need to know now.
A broader leadership and operational shift is also underway. CEO Ugur Sahin indicated at the AGM that his address may have been his last as chairman. By the end of 2026, partner Pfizer will assume full commercial production of the COVID-19 vaccines, freeing BioNTech to concentrate entirely on oncology. The buyback may cushion near-term share price pain, but the real catalyst — clinical proof that Pumitamig and the broader pipeline can deliver — rests on data releases like today’s.
Ad
BioNTech Stock: New Analysis - 21 May
Fresh BioNTech information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
